SCHEMBL25545459

SCHEMBL25545459

CC(C)CCC(=O)c1ccc(OC2CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.49
LMNA P02545 2/20 0.46
PARP10 Q53GL7 1/20 0.46
TRPA1 O75762 1/20 0.45
HRH3 Q9Y5N1 5/20 0.44
ALDH1A1 P00352 3/20 0.44
THRB P10828 2/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 1/20 0.44
KMT2A Q03164 1/20 0.43
ACACB O00763 3/20 0.42
MAPK1 P28482 1/20 0.42
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
EPHX2 P34913 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545442 0.79 MAPT (0.62) TRPA1ALDH1A1NPC1KMT2AMAPT
SCHEMBL25180868 0.78 PARP10 (0.51) LMNAPARP10ALDH1A1EPHX2
SCHEMBL17873447 0.76 GSK3B (0.58) LMNAPARP10ALDH1A1EPHX2
SCHEMBL25139633 0.76 PARP10 (0.53) LMNAPARP10HRH3ALDH1A1KMT2A
SCHEMBL11531236 0.75 MMP1 (0.59) LMNAPARP10TRPA1ALDH1A1THRB
SCHEMBL18101745 0.74 PARP10 (0.47) PARP10HRH3ALDH1A1KMT2AACACB
SCHEMBL18101744 0.74 PARP10 (0.47) LMNAPARP10HRH3ALDH1A1KMT2A
SCHEMBL25545461 0.74 PARP10 (0.44) LMNAPARP10HRH3ALDH1A1KMT2A
SCHEMBL10474694 0.73 HSD17B3 (0.62) TRPA1ALDH1A1NPC1
SCHEMBL17873483 0.73 LMNA (0.61) LMNAPARP10HRH3ALDH1A1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2025-10-23 US disclosed
US-12234231-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2025-02-25 US disclosed
EP-4392422-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-118103368-A EIF4E inhibitors and uses thereof 皮克医疗公司 2024-05-28 CN disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
WO-2023028235-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PDE4D 1923/4885LMNA 2647/4885PARP10 932/4885
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 PDE4D 1923/4885LMNA 2647/4885PARP10 932/4885
US-12234231-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 PDE4D 1923/4885LMNA 2647/4885PARP10 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.